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ABSTRACT
The overexpression of ATP binding cassette (ABC) transporters makes tumor 
cells simultaneously resistant to several cytotoxic drugs. Impairing the energy 
metabolism of multidrug resistant (MDR) cells is a promising chemosensitizing 
strategy, but many metabolic modifiers are too toxic in vivo. We previously observed 
that the aminobisphosphonate zoledronic acid inhibits the activity of hypoxia inducible 
factor-1α (HIF-1α), a master regulator of cancer cell metabolism. Free zoledronic 
acid, however, reaches low intratumor concentration. We synthesized nanoparticle 
formulations of the aminobisphosphonate that allow a higher intratumor delivery 
of the drug. We investigated whether they are effective metabolic modifiers and 
chemosensitizing agents against human MDR cancer cells in vitro and in vivo.
At not toxic dosage, nanoparticles carrying zoledronic acid chemosensitized 
MDR cells to a broad spectrum of cytotoxic drugs, independently of the type of ABC 
transporters expressed. The nanoparticles inhibited the isoprenoid synthesis and the 
Ras/ERK1/2-driven activation of HIF-1α, decreased the transcription and activity of 
glycolytic enzymes, the glucose flux through the glycolysis and tricarboxylic acid cycle, 
the electron flux through the mitochondrial respiratory chain, the synthesis of ATP. 
So doing, they lowered the ATP-dependent activity of ABC transporters, increasing 
the chemotherapy efficacy in vitro and in vivo. These effects were more pronounced 
in MDR cells than in chemosensitive ones and were due to the inhibition of farnesyl 
pyrophosphate synthase (FPPS), as demonstrated in FPPS-silenced tumors.
Our work proposes nanoparticle formulations of zoledronic acid as the first not 
toxic metabolic modifiers, effective against MDR tumors.
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INTRODUCTION
The mevalonate pathway produces cholesterol 
and isoprenoids - such as farnesyl pyrophosphate (FPP) 
and geranylgeranyl pyrophosphate - which activate 
small G-proteins like Ras and Rho. The high activity 
of the mevalonate pathway induces tumor proliferation, 
invasion and aggressiveness, and is correlated with 
poor clinical outcome of oncological patients [1, 2]. 
Hence, inhibitors of the pathway are attractive adjuvant 
anti-tumor drugs [3–5].
The overexpression of ATP binding cassette (ABC) 
transporters - such as P-glycoprotein (Pgp/ABCB1), 
multidrug resistance related proteins (MRPs/ABCCs) and 
breast cancer resistance protein (BCRP/ABCG2) - limits 
the intracellular retention and activity of several cytotoxic 
drugs, producing a multidrug resistant (MDR) phenotype 
in tumor cells [6]. MDR cells have a higher mevalonate 
pathway than chemosensitive ones [7, 8]. Since the 
activity of ABC transporters is increased by the high 
content of cholesterol in the plasma membrane [7–9], the 
inhibition of mevalonate pathway has efficiently overcome 
the MDR phenotype in vitro [7–13].
To achieve the maximal efficacy, ABC transporters 
have also a huge need of ATP [6]. ATP depleting agents 
exert higher cytotoxicity against MDR cells than against 
chemosensitive ones, inducing a phenomenon known 
as “collateral sensitivity” [14, 15]. Although ATP 
depleting agents are very effective in vitro, they are too 
toxic in vivo [16].
Zoledronic acid (ZA), a clinically used 
aminobisphosphonate that inhibits the FPP synthase 
(FPPS) step in the mevalonate pathway [17], reduces the 
activity and expression of Pgp in MDR cells by decreasing 
the amount of cholesterol in plasma membrane and 
inhibiting the Pgp transcription mediated by the hypoxia 
inducible factor-1α (HIF-1α) [8]. Of note, HIF-1α also 
increases the energy metabolism and ATP synthesis in 
cancer cells [18].
The major drawback of using ZA at clinically 
achievable concentrations is its fast uptake by bone 
tissue that limits the amount of the drug reaching the 
tumor [19]. In previous studies we demonstrated that 
ZA has a negligible effect on different tumors in vivo, in 
consequence of its low intratumor accumulation. The use 
of nanocarriers such as nanoparticles (NPs) or liposomes 
made ZA a powerful anticancer agent by improving its 
intratumor delivery [20–24]. The use of nanovectors have 
enhanced the anti-proliferative activity of ZA in a wide 
spectrum of chemosensitive tumors [20–23], but it is not 
known whether NPs carrying ZA (here termed NZ) are 
also effective against MDR tumors.
In this work we demonstrated that NZ is a strong 
chemosensitizing agent, owing to its peculiar effects on 
the energy metabolism of MDR tumors.
RESULTS
NZ inhibits the mevalonate pathway/Ras/
ERK1/2/HIF-1α/Pgp axis and sensitizes 
MDR cells to a broad spectrum of 
chemotherapeutic agents
We investigated the effects of ZA and NZ in non-small 
cell lung cancer A549 cells and in the chemoresistant 
counterpart A549/MDR cells, which had higher IC50 
values towards different cytotoxic drugs (Table 1) 
and higher expression of different ABC transporters 
(Supplementary Figure 1). The NZ particles used in this 
study had a mean diameter of about 150 nm with a narrow 
size distribution (polydispersity index – P.I. – lower than 
0.2). A deep characterization of these particles have been 
described in [20]. The IC50 of ZA, NZ and self-assembling 
nanoparticles without ZA (blank NPs) in A549 and A549/
MDR cells are provided in the Table 2: on the basis of 
these values, in all the experiments we used ZA, NZ and 
blank NPs at the not toxic concentration of 1 μM.
In A549/MDR cells NZ lowered the IC50 of different 
cytotoxic drugs, unrelated for structure, mechanism of 
action and efflux through specific ABC transporters, 
more than ZA (Table 1). Similar results were obtained 
in chemosensitive HT29 cells and in their resistant 
counterpart HT29/MDR cells (Supplementary Table 1). 
NZ and – at a lesser extent ZA – reduced the expression 
of Pgp, but did not change the levels of the other ABC 
transporters (Supplementary Figure 2).
We next analyzed if NZ reduced the mevalonate 
pathway activity, which favors the MDR phenotype 
and is inhibited by ZA [8]. NZ decreased the synthesis 
of cholesterol and FPP more than ZA, after 24 and 48 
h; its effect was stronger in A549/MDR cells, which 
had a basally higher activity than A549 cells (Figure 
1a–1b). In parallel, NZ lowered the activity of Ras and 
Ras-downstream effectors ERK1/2 (Figure 1c). HIF-1α, 
which was constitutively phosphorylated (Figure 1c) and 
bound to its DNA target sequence (Figure 1d) in A549/
MDR cells, is a substrate of ERK [25]. NZ reduced the 
HIF-1α amount, phosphorylation and DNA binding 
(Figure 1c–1d), and lowered the transcription of the HIF-
1α-target gene Pgp (Figure 1e) in MDR cells.
We next looked for potential mechanisms explaining 
the chemosensitizing effects of NZ on drugs that are not 
substrates of Pgp.
By reducing HIF-1α activity, NZ decreases the 
glycolytic flux and the ATP levels in MDR cells
Compared to A549 cells, A549/MDR cells 
had higher expression of the HIF-1α-target genes 
glucose transporter 1 (GLUT1), hexokinase (HK), 
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phosphofructokinase-1 (PFK1), aldolase-A (ALDO-A), 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH), 
phosphoglycerate kinase (PGK), enolase-A (ENO-A), 
pyruvate kinase (PK), lactate dehydrogenase (LDH; 
Figure 2), which are involved in glucose uptake 
and metabolism. NZ down-regulated all these genes 
(Figure 2), as well as other canonical HIF-1α-target genes, 
such as vascular endothelial growth factor, erythropoietin, 
carbonic anhydrase IX and XII (Supplementary Figure 3), 
in MDR cells.
In keeping with the higher expression of the 
glycolytic genes, A549/MDR cells showed higher uptake of 
glucose (Figure 3a), higher activity of PFK-1 (Figure  3b), 
GAPDH (Figure 3c), enolase (Figure 3d), PK (Figure 3e) 
and LDH (Figure 3f), higher flux of glucose into the 
tricarboxylic acid (TCA) cycle (Figure 3g), higher levels 
of ATP (Figure 3h). NZ significantly reduced all these 
parameters more efficiently than ZA. Again NZ was 
more  effective in A549/MDR cells than in A549 cells 
(Figure 3a–3h).
Table 2: IC50 (μM) of ZA, NZ and blank NPs in A549 and A549/MDR cells
Sample A549 A549/MDR
ZA >120 89.62 ± 7.81
NZ 20.22 ± 1.23 *,° 20.78 ± 1.82 *,°
NB >120 >120
A549 and A549/MDR cells were incubated for 72 h with increasing concentrations of ZA, NZ or blank NPs (NB), then 
stained in quadruplicate with neutral red (n = 3). Versus NB, in each cell line: *p < 0.001; versus ZA, in each cell line:  
°p < 0.001.
Table 1: IC50 (μM) of different chemotherapeutic drugs in A549 and A549/MDR cells
A549 A549 A549 A549/MDR A549/MDR A549/MDR
Drug Transporter CTRL ZA NZ CTRL ZA NZ
doxorubicin
Pgp, MRP1, 
MRP2, MRP3, 
BCRP
0.53 ± 0.06 0.41 ± 0.07 0.36 ± 0.07 * 1.83 ± 0.14° 1.53 ± 0.12 1.01 ± 0.18 *
vinblastine Pgp, MRP1, MRP2 2.34 ± 0.25 1.24 ± 0.12 * 0.78 ± 0.13 *
12.37 ± 
0.21° 5.41 ± 0.64 * 1.86 ± 0.44 *
etoposide
Pgp, MRP1, 
MRP2, MRP3 3.25 ± 0.12 0.87 ± 0.14 * 0.51 ± 0.12 * 8.33 ± 0.44° 5.43 ± 0.27 * 0.91 ± 0.12 *
irinotecan Pgp, MRP1, MRP2 4.21 ± 0.15 3.37 ± 0.12 2.11 ± 0.12 * 8.11 ± 0.42° 6.77 ± 0.43 3.33 ± 0.41 *
cisplatin MRP1, MRP2, MRP4 8.11 ± 0.44 1.37 ± 0.09 * 0.81 ± 0.11 *
12.88 ± 
0.21° 1.97 ± 0.27 * 0.65 ± 0.12 *
oxaliplatin MRP1, MRP4 2.87 ± 0.14 1.34 ± 0.17 * 1.03 ± 0.12 * 5.20 ± 0.32° 3.21 ± 0.17 * 1.86 ± 0.31 *
5-fluorouracile
MRP1, MRP3, 
MRP4, MRP5 4.42 ± 0.18 4.11 ± 0.17 4.26 ± 0.09 7.01 ± 0.45° 5.88 ± 0.36 5.15 ± 0.12
methotrexate
MRP4, Pgp, 
MRP1, MRP2, 
MRP3, BCRP
3.27 ± 0.11 1.88 ± 0.28 * 0.61 ± 0.14 * 9.37 ± 0.63° 8.67 ± 1.09 4.32 ± 0.67 *
pemetrexed MRP5 0.51 ± 0.11 0.25 ± 0.08 * 0.07 ± 0.02 * 11.21 ± 0.87° 8.76 ± 0.77 2.51 ± 0.47 *
gemcitabine MRP5 0.07 ± 0.02 0.04 ± 0.01 * 0.03 ± 0.01 * 0.88 ± 0.15° 0.81 ± 0.13 0.12 ± 0.04 *
mitoxantrone
BCRP, Pgp, 
MRP1 10.22 ± 0.88 5.24 ± 0.67 * 1.17 ± 0.18 *
17.88 ± 
0.67° 12.33 ± 0.73 2.67 ± 0.25 *
Untreated (CTRL) A549 and A549/MDR cells, cells treated with 1 μM ZA or NZ, were incubated for 72 h with increasing 
concentrations of chemotherapeutic drugs, then stained in quadruplicate with neutral red (n = 3). Versus respective CTRL: 
*p < 0.02; A549/MDR versus A549 cells: °p < 0.005.
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Figure 1: NZ lowers the mevalonate pathway/Ras/ERK1/2/HIF1α axis and Pgp expression in MDR cancer 
cells. Chemosensitive human lung cancer A549 cells and their resistant counterpart A549/MDR cells were grown for 24 (panel a-b) or 
48 h (panel a–e) in fresh medium (-), in medium containing 1 μM zoledronic acid (ZA) or 1 μM self-assembling ZA formulation (NZ). 
a–b. Cells were radiolabelled during the last 24 h with [3H]-acetate, then the de novo synthesis of cholesterol (panel a) or FPP (panel b) 
was measured. Data are presented as means ± SD (n = 3). For both panels, versus untreated A549 cells: *p < 0.05; versus untreated A549/
MDR cells: °p < 0.005. c. Cells were lysed and subjected to the Western blot analysis for Ras-GTP, Ras, phospho(Thr202/Tyr204, Thr185/
Tyr187)-ERK1/2, ERK1/2, phospho(Ser)-HIF-1α, HIF-1α. The β-tubulin expression was used as control of equal protein loading. The 
figure is representative of 3 experiments. d. HIF-1α activity was measured in nuclear extracts by ELISA. Data are presented as means 
± SD (n = 4). Versus untreated A549 cells: *p < 0.05; versus untreated A549/MDR cells: ° p < 0.001. e. Pgp mRNA levels were detected 
in triplicate by qRT-PCR. Data are presented as means ± SD (n = 4). Versus untreated A549 cells: *p < 0.001; versus untreated A549/MDR 
cells: °p < 0.001.
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NZ inhibits the mitochondrial metabolism and 
increases the reactive oxygen species production 
in MDR cells
The synthesis of ubiquinone, whose isoprenoid tail 
is a side product of the mevalonate pathway, was higher 
in A549/MDR cells than in A549 cells (Figure 4a). The 
higher amount of ubiquinone was paralleled by the higher 
activity of the respiratory chain (Figure 4b) and by the 
higher level of mitochondrial ATP (Figure 4c). NZ and ZA 
reduced the electron flux and the ATP levels proportionally 
to their ability to decrease ubiquinone (Figure 4a–4c).
NZ also increased the reactive oxygen species 
(ROS) in A549 and A549/MDR cells (Figure 4d–4e).
NZ reduces the efflux activity of ABC 
transporters and increases the intracellular drug 
retention in MDR cells
Since doxorubicin is a substrate of Pgp, MRP1, 
MRP2, MRP3 and BCRP [6], we measured its efflux 
kinetics as a sensitive index of the activity of these 
transporters. As expected, A549/MDR cells had a higher 
Vmax of doxorubicin efflux than A549 cells (Figure 5a). 
Neither ZA nor NZ changed the Vmax in A549 cells 
(Figure 5a). By contrast, NZ and – at lesser extent – ZA 
decreased the Vmax in A549/MDR cells (Figure 5a). 
Moreover NZ increased the doxorubicin Km, suggesting 
that it reduced the affinity of the drug for the transporters. 
The intracellular accumulation of doxorubicin, carboplatin 
(a substrate of MRP1, MRP2, MRP4), gemcitabine 
(a substrate of MRP5) and mitoxantrone (a substrate of 
BCRP, Pgp, MRP1) were all significantly increased by NZ 
in A549/MDR cells (Figure 5b–5e).
The chemosensitizing effect of NZ is due to the 
inhibition of FPPS
The chemosensitizing properties of NZ were not 
due to the use of the NPs scaffold: indeed blank NPs 
did not reduce the activity of mevalonate pathway, the 
activation of HIF-1α, the levels of ATP, the transcription 
of Pgp and the efflux of doxorubicin in A549/MDR cells 
(Supplementary Figure 4a–4e).
To investigate whether the properties of NZ were 
due to the inhibition of the ZA-target enzyme FPPS, we 
produced a A549/MDR subclone inducibly knocked-down 
for FPPS (Figure 6a). As expected, FPPS-silenced A549/
MDR cells had extremely low levels of cholesterol, FPP 
and ubiquinone (Supplementary Figure 5a–5c). Moreover, 
they had lower activity of Ras and ERK1/2 (Figure 6b), 
lower phosphorylation (Figure 6b) and DNA binding of 
Figure 2: NZ reduces the expression of glycolytic genes in MDR cancer cells. Chemosensitive human lung cancer A549 cells 
and their resistant counterpart A549/MDR cells were grown for 48 h in fresh medium (-), in medium containing 1 μM zoledronic acid 
(ZA) or 1 μM self-assembling ZA formulation (NZ). GLUT1, HK, PFK1, ALDO-A, GAPDH, PGK, ENO-A, PK, LDH mRNA levels were 
detected in triplicate by qRT-PCR. Data are presented as means ± SD (n = 4). For all panels, versus untreated A549 cells: *p < 0.05; versus 
untreated A549/MDR cells: ° p < 0.01.
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Figure 3: NZ decreases glucose uptake, glycolysis, tricarboxylic acid cycle, ATP levels in MDR cancer cells. Chemosen 
sitive human lung cancer A549 cells and their resistant counterpart A549/MDR cells were cultured for 48 h in fresh medium (-), in 
medium containing 1 μM zoledronic acid (ZA) or 1 μM self-assembling ZA formulation (NZ). a. The uptake of 2-deoxy-D-[3H]-glucose 
within living cells was measured and quantified by liquid scintillation. Data are presented as means ± SD (n = 3). Versus untreated A549 
cells: *p < 0.002; versus untreated A549/MDR cells: °p < 0.001. b–e. The enzymatic activity of phosphofruttokinase-1 (PFK1; panel b), 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH; panel c), enolase (panel d), pyruvate kinase (PK; panel e), lactate dehydrogenase 
(LDH; panel f.) was measured in cell lysates. Data are presented as means ± SD (n = 3). For all panels, versus untreated A549 cells: 
*p < 0.05; versus untreated A549/MDR cells: °p < 0.002. g. The glucose flux through glycolysis and TCA cycle was measured in the whole 
cell radiolabelled with [6-14C]-glucose. Data are presented as means ± SD (n = 3). Versus untreated A549 cells: *p < 0.01; versus untreated 
A549/MDR cells: °p < 0.002. h. ATP levels were measured in living cells by a chemiluminescence-based assay. Data are presented as 
means ± SD (n = 3). Versus untreated A549 cells: *p < 0.001; versus untreated A549/MDR cells: °p < 0.002.
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HIF-1α (Figure 6c), lower glucose flux into glycolysis and 
TCA cycle (Figure 6d), lower mitochondrial respiratory 
activity (Figure 6e), lower levels of total (Figure 6f) and 
mitochondrial (Figure 6g) ATP, reproducing the same 
metabolic effects of NZ.
FPPS-silenced A549/MDR cells were also more 
sensitive to several cytotoxic drugs than parental A549/
MDR cells (Table 3), as it occurred for A549/MDR cells 
treated with NZ.
NZ reverses drug resistance in human lung 
cancer xenografts
In keeping with the in vitro results, doxorubicin 
and carboplatin reduced the growth of A549 xenografts, 
but not of A549/MDR ones. NZ rescued the antitumor 
efficacy of these chemotherapeutic drugs in MDR tumors 
(Figure 7a). Of note, NZ did not increase liver, heart and 
kidney toxicity, as suggested by the hematochemical 
Figure 4: NZ reduces the mitochondrial respiratory chain activity and increases ROS in MDR cancer cells. Chemosen 
sitive human lung cancer A549 cells and their resistant counterpart A549/MDR cells were grown for 24 (panel a, d, e) or 48 h (panel 
a–e) in fresh medium (-), in medium containing 1 μM zoledronic acid (ZA) or 1 μM self-assembling ZA formulation (NZ). a. Cells were 
radiolabelled during the last 24 h with [3H]-acetate, then the de novo synthesis of ubiquinone was measured. Data are presented as means 
± SD (n = 3). Versus untreated A549 cells: *p < 0.05; versus untreated A549/MDR cells: °p < 0.005. b. The ubiquinone-independent (i.e. 
without Complex I inhibitor rotenone) and ubiquinone-dependent (i.e. with 50 μM rotenone) electron flux between Complex I and III 
was measured spectrophotometrically in isolated mitochondria. Data are presented as means ± SD (n = 3). Versus untreated A549 cells: 
*p < 0.01; versus untreated A549/MDR cells: °p < 0.001. c. ATP levels were measured in mitochondrial extracts by a chemiluminescence-
based assay. Data are presented as means ± SD (n = 3). Versus untreated A549 cells: *p < 0.05; versus untreated A549/MDR cells: 
°p < 0.001. d. ROS levels were measured by flow cytometry with the DHE method. H2O2 (500 μM), a ROS inducer in both chemosensitive 
and MDR cells, doxorubicin (1 μM, dox), a ROS inducer in chemosensitive but not in MDR cells, N-acetylcysteine (2 mM, NAC), an 
antioxidant agent, were used as internal controls. CTRL -: cells not labelled with DHE, used as negative control. CTRL: cells labelled with 
DHE, used as control of the cell autofluorescence. The figure is representative of 3 experiments. e. Mean fluorescence intensity (MFI) 
obtained in the flow cytometry experiments of panel d. Data were calculated with the Cell Quest software and are presented as means ± SD 
(n = 3). Versus CTRL: *p < 0.05; H2O2 + NAC versus H2O2 alone: °p < 0.05.
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parameters of the animals (Supplementary Table 2). 
Similarly to what observed in NZ-treated mice, the 
FPPS-silencing rescued the efficacy of doxorubicin and 
carboplatin in A549/MDR xenografts (Figure 7b).
DISCUSSION
In this work we investigated the potential use of 
self-assembling NPs encapsulating ZA, here named NZ, 
Figure 5: NZ reduces the efflux and increases the intracellular retention of chemotherapeutic drugs. a. Chemosensitive 
human lung cancer A549 cells and their resistant counterpart A549/MDR cells were grown for 48 h in fresh medium, then incubated for 
20 min with increasing concentrations (0–50 μmol/l) of doxorubicin (dox). When indicated, cells were pre-treated for 48 h with 1 μM 
zoledronic acid (ZA) or 1 μM self-assembling ZA formulation (NZ), then incubated with doxorubicin (dox + ZA or dox + NZ, respectively). 
Cells were washed and tested for the intracellular drug content. The procedure was repeated on a second series of dishes, incubated in the 
same experimental conditions and analyzed after 10 min. Data are presented as means ± SD (n = 3). The rate of doxorubicin efflux (dc/dt) 
was plotted versus the initial concentration of the drug. Vmax (nmol/min/mg proteins) and Km (nmol/mg proteins) were calculated with the 
Enzfitter software. Versus dox: *p < 0.05. b–e. Cells were cultured for 48 h in fresh medium (-), in medium containing 1 μM zoledronic acid 
(ZA) or 1 μM self-assembling ZA formulation (NZ), then incubated for 3 h with 5 μM doxorubicin (dox; panel b), 1 μCi [14C]-carboplatin 
(Pt; panel c), 0.5 μCi [3H]-gemcitabine (gem; panel d), 10 μM mitoxantrone (MXR; panel e). Cells were lysed and the amount of each drug 
was measured. Data are presented as means ± SD (n = 4). For all panels, versus untreated A549 cells: *p < 0.05; versus untreated A549/
MDR cells: °p < 0.05.
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as not toxic metabolic modifiers and inducers of collateral 
sensitivity against human MDR cells.
NZ decreased the expression of Pgp, without 
changing the expression of other ABC transporters, but 
it chemosensitized MDR cells also to cytotoxic agents 
that are not Pgp substrates. Such mechanism is extremely 
surprising in the field of chemosensitizing agents, because 
up-to-day most chemosensitizer compounds inhibit one or 
few specific ABC transporters [16, 26].
By decreasing the synthesis of cholesterol, 
which is critical for the activity of Pgp [7, 8], and the 
activity of Ras/ERK1/2/HIF-1α-axis, which mediates 
Figure 6: FPPS silencing produces the same metabolic signature of NZ in MDR cells. Wild-type (-) A549/MDR cells, cells 
treated with a TetON vector containing a shRNA targeting FPPS (sh) or a non targeting scrambled shRNA (scr), were cultured 48 h in 
medium without (-) or with (+) 1 μg/ml doxycycline (doxy). a. Western blot analysis of FPPS. The β-tubulin expression was used as control 
of equal protein loading. The figure is representative of 3 experiments. b. Western blot analysis for Ras-GTP, Ras, phospho(Thr202/Tyr204, 
Thr185/Tyr187)-ERK1/2, ERK1/2, phospho(Ser)-HIF-1α, HIF-1α. The β-tubulin expression was used as control of equal protein loading. 
The figure is representative of 3 experiments. c. HIF-1α activity was measured in nuclear extracts by ELISA. Data are presented as means 
± SD (n = 4). Versus untreated (- doxy) cells: *p < 0.001. d. The glucose flux through glycolysis and TCA cycle was measured by metabolic 
radiolabelling. Data are presented as means ± SD (n = 3). Versus untreated (- doxy) cells: *p < 0.001. e. The ubiquinone-independent 
(i.e. without Complex I inhibitor rotenone) and ubiquinone-dependent (i.e. with 50 μM rotenone) electron flux between Complex I and 
III was measured spectrophotometrically in isolated mitochondria. Data are presented as means ± SD (n = 3). Versus untreated (- doxy) 
cells: *p < 0.005. f–g. Whole cell (panel f) and mitochondrial (panel g) ATP was measured by a chemiluminescence-based assay. Data are 
presented as means ± SD (n = 3). For both panels, versus untreated (- doxy) cells: *p < 0.001.
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the transcription of Pgp [8], NZ reversed the resistance 
towards Pgp substrates.
The chemosensitization towards cytotoxic agents 
that are not substrates of Pgp was due to the effects on the 
energy metabolism of MDR cells.
Many HIF-1α-target genes involved in the glycolytic 
flux were up-regulated in MDR cells if compared with 
chemosensitive ones. This condition, which is compatible 
with the Warburg effect observed in many solid tumors, 
increased the glucose flux through the glycolysis and 
TCA cycle, and the intracellular levels of ATP. Also 
the electron flux through the mitochondrial respiratory 
chain and the mitochondrial synthesis of ATP were 
increased in MDR cells. Such increase can be explained 
by the higher supply of reducing equivalents through the 
accelerated TCA cycle and/or by the higher levels of the 
electron shuttle ubiquinone, which is a side product of the 
mevalonate pathway. Chemoresistant cells often activate 
both glycolysis and oxidative phosphorylation to ensure 
an adequate supply of ATP [27], which is constantly 
hydrolyzed by ABC transporters. This observation 
is in keeping with the metabolic profile of our MDR 
cells, which had higher activity of both anaerobic and 
aerobic energy pathways and higher expression of ABC 
transporters than chemosensitive cells.
On the other hand, MDR cells show a paradoxical 
hypersensitivity - the so called “collateral sensitivity” - to 
agents lowering ATP or inducing oxidative stress [14, 15].
Our work suggests that NZ is a strong inducer of 
collateral sensitivity: it reduced glucose anaerobic and 
aerobic metabolism, increased ROS production and 
lowered intracellular ATP, by decreasing the mevalonate 
pathway/Ras/ERKs/HIF-1α axis and the supply of 
ubiquinone to the mitochondrial respiratory chain. As a 
consequence, NZ reduced the ATP-dependent activity of 
ABC transporters in MDR cells, increased the intracellular 
retention and cytotoxicity of multiple chemotherapeutic 
agents in vitro and in vivo.
These results are in line with previous data showing 
that agents depleting cellular ATP [28] or lowering glucose 
Table 3: IC50 (μM) of different chemotherapeutic drugs in A549/MDR cells inducibly silenced 
for FPPS
− doxy − doxy − doxy + doxy + doxy + doxy
Drug Transporter CTRL shRNA 
FPPS
scrambled CTRL shRNA 
FPPS
scrambled
doxorubicin
Pgp, MRP1, 
MRP2, MRP3, 
BCRP
1.91 ± 0.15 1.80 ± 0.08 1.74 ± 0.17 1.81 ± 0.13 0.50 ± 0.15* 1.87 ± 0.21
vinblastine Pgp, MRP1, MRP2 10.71 ± 1.01 10.22 ± 0.98 12.09 ± 1.09 11.88 ± 0.41 0.78 ± 0.18* 10.72 ± 0.35
etoposide
Pgp, MRP1, 
MRP2, MRP3 9.12 ± 0.56 8.81 ± 0.27 9.01 ± 0.71 9.01 ± 0.59 0.31 ± 0.04* 8.36 ± 0.61
irinotecan Pgp, MRP1, MRP2 8.92 ± 0.62 9.07 ± 0.45 7.99 ± 0.56 8.76 ± 0.51 1.01 ± 0.21* 9.02 ± 0.49
cisplatin MRP1, MRP2, MRP4 11.67 ± 0.61 10.98 ± 0.41 11.78 ± 0.91 11.23 ± 0.81 0.22 ± 0.0* 12.12 ± 0.67
oxaliplatin MRP1, MRP4 4.92 ± 0.34 4.31 ± 0.27 5.11 ± 0.22 5.07 ± 0.27 0.57 ± 0.25* 5.11 ± 0.41
5-fluorouracile
MRP1, MRP3, 
MRP4, MRP5 7.22 ± 0.09 7.31 ± 0.21 8.00 ± 0.39 6.88 ± 0.26 1.39 ± 0.21* 7.01 ± 0.62
methotrexate
MRP4, Pgp, 
MRP1, MRP2, 
MRP3, BCRP
9.61 ± 0.71 8.99 ± 0.41 9.16 ± 0.17 8.81 ± 0.24 0.71 ± 0.13* 9.31 ± 0.38
pemetrexed MRP5 10.93 ± 0.62 10.23 ± 0.81 10.91 ± 0.42 11.08 ± 0.54 0.13 ± 0.04* 11.25 ± 0.54
gemcitabine MRP5 0.77 ± 0.11 0.84 ± 0.09 0.81 ± 0.07 0.91 ± 0.04 0.05 ± 0.01* 0.82 ± 0.12
mitoxantrone
BCRP, Pgp, 
MRP1 19.02 ± 0.71 18.11± 0.91 17.99 ± 0.42 18.28 ± 0.72 0.27 ± 0.03* 18.56 ± 0.81
Untreated (CTRL) A549/MDR cells, cells treated with the shRNA targeting FPPS (shRNA FPPS) or with a non targeting 
scrambled shRNA (scrambled), in the absence (−) or presence (+) of 1 μg/ml doxycycline (doxy), were incubated for 72 h with 
increasing concentrations of chemotherapeutic drugs, then stained in quadruplicate with neutral red (n = 3). Versus - doxy: 
*p < 0.001.
Oncotarget31471www.impactjournals.com/oncotarget
uptake and oxidative phosphorylation [29] overcome 
chemoresistance. Differently from other ATP depleting 
agents, which are highly toxic [16], NZ chemosensitized 
MDR cells at a concentration (1 μM) not toxic in our 
animal models and compatible with the concentration of 
ZA found in patients [30, 31].
Interestingly, NZ was significantly more effective 
in MDR cells than in chemosensitive ones. By targeting 
the mevalonate pathway and the activity of HIF-1α, 
which are basally more active in chemoresistant cells, 
NZ exploited two metabolic features that are crucial to 
maintain the MDR phenotype. The linkage between the 
inhibition of the mevalonate pathway and the resulting 
chemosensitizing effects was demonstrated by FPPS-
silenced cells, which reproduced the same phenotype of 
NZ-treated MDR cells.
Chemoresistant cells often activate multiple 
survival pathways in response to stress conditions, 
such as JAK/STAT3 axis, Akt/mTOR axis, peroxisome 
proliferator activated receptor gamma-dependent 
pathways and cyclooxygenase 2-dependent pathways: 
these redundant pro-survival pathways promote cell 
proliferation and inhibit apoptosis, contributing to 
drug resistance [32–34]. We recently observed that 
JAK/STAT3 axis is constitutively activated in MDR 
cells [35] and that ZA inhibits it by reducing the Ras/
ERK1/2 activity [13]. Moreover, it has been reported 
that ZA effects can be mediated by peroxisome 
proliferator activated receptor gamma [36] and 
cyclooxygenase 2 [37] activity. We cannot exclude that 
ZA and NZ chemosensitized A549/MDR cells also by 
targeting some of these pathways.
Figure 7: NZ reverts chemoresistance in lung xenografts. a. Six weeks-old female BALB/c mice bearing a 100 mm3 A549 or 
A549/MDR tumor were randomly divided into 6 groups (5 mice/group) and treated with saline solution (Ctrl), NZ, doxorubicin (dox), NZ + 
doxorubicin (NZ+dox), carboplatin (Pt), NZ + carboplatin (NZ + Pt), as detailed under Materials and Methods. The experiment was repeated 
2 times. For A549 tumors, all treatment groups versus Ctrl group (day 21): *p < 0.01. For A549/MDR tumors, NZ+dox/NZ+Pt versus Ctrl 
group: *p < 0.01; NZ+dox/NZ+Pt versus dox or Pt group: °p < 0.005. b. Six weeks-old female BALB/c mice bearing a 100 mm3 A549/MDR 
tumor inducibly silenced for FPPS were randomly divided into 3 groups (5 mice/group): Ctrl group; doxorubicin group (dox); carboplatin 
group (Pt), treated as detailed under Materials and Methods, without (-) or with (+) 1 mg/ml doxycycline (doxy) in the drinking water. The 
experiment was repeated 2 times. Dox/Pt group versus Ctrl -doxy group: *p < 0.005; dox/Pt group versus Ctrl +doxy group: °p < 0.01.
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The use of drugs encapsulated within liposomes has 
been proposed as an effective strategy to overcome the 
drug resistance mediated by ABC transporters [38], for 
the different kinetics of drug release [39, 40], the different 
drug intracellular distribution [40, 41], the reduction of 
Pgp expression and activity [41–43], the changes in the 
lipid environment where Pgp works [44, 45].
We excluded that the chemosensitizing effect of 
NZ was due to the liposomal envelope, because self-
assembling NPs without ZA did not reverse the MDR 
phenotype. On the other hand, it is known that NZ 
induces greater anti-proliferative effects than free ZA on 
tumor cells, because the use of NPs produced a higher 
intratumor uptake of the aminobisphosphonate [19–24]. 
Also in this study, the greater efficacy of NZ over free 
ZA can be explained by the higher uptake of ZA when 
administered as NZ.
Our work unveils that NPs encapsulating ZA reverse 
the MDR phenotype by inhibiting the mevalonate pathway 
and the HIF-1α-dependent signaling, two events that 
impair the energy metabolism and the activity of ABC 
transporters (Figure 8). These observations may pave the 
way to the pre-clinical use of NZ, in combination with 
other cytotoxic drugs, as the first not toxic metabolic 
modifier, effective against MDR tumors.
MATERIALS AND METHODS
Ethics statement
Investigation has been conducted in accordance 
with the ethical standards, according to the Declaration 
of Helsinki, national and international guidelines, and has 
been approved by the authors’ institutional review board.
Figure 8: Metabolic basis of the chemosensitizing effects of NZ in MDR cells. Self-assembling nanoparticles encapsulating 
zoledronic acid (NZ) inhibit the farnesyl pyrophosphate synthase (FPPS) step in the mevalonate (Mev) pathway. So doing, NZ reduces 
the Ras/ERK1/2/HIF-1α-mediated transcription of P-glycoprotein (Pgp), the transcription of glycolytic genes, the synthesis of ubiquinone 
(UQ) and the mitochondrial electron flux, thus limiting the supply of ATP for Pgp, multidrug resistance related proteins (MRPs) and breast 
cancer resistance protein (BCRP). Overall these events increase the intracellular retention and toxicity of chemotherapeutic drugs (d).
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Chemicals
Fetal bovine serum and culture medium were 
from Invitrogen Life Technologies (Carlsbad, CA). 
Plasticware for cell cultures was from Falcon (Becton 
Dickinson, Franklin Lakes, NJ). Dihydroethidium (DHE), 
N-acetylcysteine (NAC) and H2O2 were purchased from 
Sigma-Aldrich (Milan, Italy). ZA was a gift from Novartis 
(Basel, Switzerland). Electrophoresis reagents were 
obtained from Bio-Rad Laboratories (Hercules, CA). 
The protein content of cell monolayers and lysates was 
assessed with the BCA kit from Sigma-Aldrich. Unless 
otherwise specified, all the other reagents were purchased 
from Sigma-Aldrich.
Preparation and characterization of NZ
Self-assembling NPs encapsulating ZA were 
prepared as previously reported [20]. Briefly, an 
aqueous solution of 18 mM CaCl2 was added, dropwise 
and under magnetic stirring, to an aqueous solution of 
10.8 mM Na2HPO4. The resulting suspension (termed 
CaPNPs) was filtered through a 0.22 μm polycarbonate 
filter (MF-Millipore, Microglass Heim, Italy) and 
stored at 4°C before use. ZA was then complexed with 
CaPNPs (to obtain CaPZNPs), at a volume ratio of 
50:1, with a final ZA concentration of 50 mg/ml. 
Cationic liposomes (N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-
trimethylammonium chloride/cholesterol/1,2-distearoyl-sn-
glycero-3-phosphoethanolamine-N-[amino(polyethylene 
glycol)-2000] at a ratio of 1:1:0.5) were prepared by 
hydration of a thin lipid film followed by extrusion. The 
lipid mixture dissolved in chloroform/methanol (2:1 
v/v) was added to a 50 ml round-bottom flask and the 
solvent was removed under reduced pressure by a rotary 
evaporator (Laborota 4010 digital, Heidolph, Schwabach, 
Germany) in nitrogen atmosphere. The resulting lipid 
film was hydrated with 1 ml of 0.22 μm-filtered distilled 
water and the resulting suspension was gently mixed 
in the presence of glass beads followed by incubation 
at room temperature for 2 h. The liposome suspension 
was then extruded using a thermobarrel extruder system 
(Northern Lipids Inc., Vancouver, BC, Canada) passing 
repeatedly the suspension under nitrogen atmosphere 
through polycarbonate membranes with decreasing pore 
sizes from 400 to 100 nm (Nucleopore Track Membrane 
25 mm, Whatman, Brentford, UK). The liposomes were 
stored at 4°C. Each formulation was prepared in triplicate. 
Finally, equal volumes of suspensions of the liposomes 
and CaPZNPs, respectively, were mixed in a glass tube 
and the resulting dispersion was maintained at room 
temperature for 10 min. NPs without ZA (blank NPs) were 
also prepared similarly, starting from CaPNPs and cationic 
liposomes. Each formulation was prepared in triplicate.
The mean diameter of stealth liposomes and 
CaPZNPs were determined at 20°C by photon correlation 
spectroscopy (N5, Beckman Coulter, Miami, FL). 
Each sample was diluted in deionizer/filtered water 
and analyzed with detector at 90° angle. P.I. was used 
as measure of the particle size distribution. For each 
batch, the mean diameter and size distribution were the 
mean of three measures. For each formulation, the mean 
diameter and P.I. were calculated as the mean of three 
different batches. The zeta potential (ζ) of the NPs surface 
was measured in water by means of a Zetasizer Nano Z 
(Malvern, UK). Data of ζ were collected as the average of 
20 measurements.
Encapsulation efficiency of ZA
ZA dosage was carried out as previously 
reported [20]. 1 ml of NPs dispersion was ultra-centrifuged 
(Optima Max E, Beckman Coulter) at 80,000 x g at 4°C 
for 40 min. Supernatants were carefully removed and ZA 
concentration was determined by high pressure liquid 
chromatography. The ZA encapsulation efficiency into 
CaPZNPs was calculated as [(TSZA – ASZA)/TSZA] × 100, 
where TSZA is the theoretical ZA in the supernatant and 
ASZA is the actual ZA concentration in the supernatant. For 
each formulation, the results are the mean of measures on 
three different batches.
Cells
Human chemosensitive non-small cell lung 
cancer A549 cells were cultured in HAM’s F12 medium 
supplemented with 10% fetal bovine serum, 1% 
penicillin-streptomycin and 1% L-glutamine, and were 
maintained in a humidified atmosphere at 37°C and 
5% CO2. A549/MDR cells were generated by culturing 
parental A549 cells in medium containing increasing 
concentrations of doxorubicin for 30 passages and then 
maintaining cells at a final concentration of 100 nM 
doxorubicin. HT29 and HT29/MDR cells have been 
already described [8, 46].
Cytotoxicity assay
Cell viability was measured by the neutral red 
staining method as previously reported [46]. The 
absorbance of untreated cells was considered as 100% 
viability; the results were expressed as percentage of 
viable cells versus untreated cells. IC50 was considered the 
concentration of each drug that reduces to 50% the cell 
viability versus untreated cells.
Mevalonate pathway activity
Cells were labelled with 1 μCi/ml [3H]-acetate 
(3600 mCi/mmol; Amersham Bioscience, Piscataway, NJ). 
The synthesis of radiolabelled cholesterol, FPP and 
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ubiquinone was measured as described in [8, 47]. Results 
were expressed as fmol [3H]cholesterol or [3H]FPP or [3H]
ubiquinone/10 6 cells, according to the relative calibration 
curve.
Ras activation assay
The Ras GTP-bound fraction, taken as an index of 
active Ras, was measured using a pull-down assay with 
the Raf-1-GST fusion protein, agarose beads-conjugates 
(Millipore, Billerica, MA). The immunoprecipitated 
samples were probed with an anti-Ras (Millipore) 
antibody.
Western blot
Cells were rinsed in lysis buffer (125 mM Tris-
HCl, 750 mM NaCl, 1% v/v NP40, 10% v/v glycerol, 
50 mM MgCl2, 5 mM EDTA, 25 mM NaF, 1 mM NaVO4, 
10 μg/ml leupeptin, 10 μg/ml pepstatin, 10 μg/ml 
aprotinin, 1 mM phenylmethylsulfonyl fluoride, pH 7.5), 
sonicated and centrifuged at 13,000 x g for 10 min at 4°C. 
20 μg cell lysates were subjected to Western blotting and 
probed with the following antibodies: phospho-(Thr202/
Tyr204, Thr185/Tyr187)-ERK1/2 (Millipore); ERK1/2 
(Millipore); HIF-1α (BD Bioscience, San Jose, CA); 
FPPS (Abcam, Cambridge, UK); Pgp/ABCB1 (Santa 
Cruz Biotechnology Inc., Santa Cruz, CA); MRP1/
ABCC1 (Abcam); MRP2/ABCC2 (Abcam); MRP3/
ABCC3 (Santa Cruz Biotechnology Inc.); MRP4/ABCC4 
(Abcam); MRP5/ABCC5 (Santa Cruz Biotechnology 
Inc.); BCRP/ABCG2 (Santa Cruz Biotechnology Inc.); 
β-tubulin (Santa Cruz Biotechnology Inc.), followed by 
the secondary peroxidase-conjugated antibodies (Bio-
Rad Laboratories). Proteins were detected by enhanced 
chemiluminescence (PerkinElmer, Waltham, MA). To 
assess HIF-1α phosphorylation, the whole cell lysate 
was immunoprecipitated with a polyclonal anti-HIF-1α 
antibody (Santa Cruz Biotechnology Inc.), then resolved 
by SDS-PAGE and probed with a biotin-conjugated anti-
phosphoserine antibody (Sigma-Aldrich), followed by 
polymeric streptavidin-horseradish peroxidase-conjugates 
(Sigma-Aldrich).
HIF-1α activity
Nuclear proteins were extracted using the Nuclear 
Extract Kit (Active Motif, Rixensart, Belgium). 
The activity of HIF-1 was assessed with the TransAM™ 
HIF-1 Transcription Factor Assay Kit (Active Motif) 
on 10 μg nuclear proteins. Data were expressed as U 
absorbance/mg nuclear proteins.
Quantitative real time-PCR (qRT-PCR)
Total RNA was extracted and reverse-transcribed 
using the QuantiTect Reverse Transcription Kit (Qiagen, 
Hilden, Germany). qRT-PCR was carried out with IQ™ 
SYBR Green Supermix (Bio-Rad Laboratories). Primers 
sequence is listed in the Supplementary Table 3. The 
relative quantitation of each sample was performed using 
the Gene Expression Quantitation software (Bio-Rad 
Laboratories).
Glucose uptake, enzymatic assays and TCA cycle 
activity
The uptake of glucose was measured as described 
earlier [48] and expressed as pmol 2-deoxy-D-[3H]-
glucose/mg cell proteins. PFK1 assay was performed 
according to [49]. The activities of GAPDH, enolase, 
LDH were measured as reported in [50]. The activity of 
PK was detected with the Enzymatic Assay of Pyruvate 
Kinase kit (Sigma-Aldrich). Results were expressed as 
nmol NAD+/min/mg cell proteins (for PFK1, enolase, PK, 
LDH) or nmol NADH/min/mg cell proteins (for GAPDH). 
The glucose flux through glycolysis and TCA cycle was 
measured as described in [51] and expressed as pmol 
CO2/h/mg cell proteins.
ATP measurement
The ATP level in whole cells and mitochondria 
extracts was measured with the ATP Bioluminescent 
Assay Kit (FL-AA, Sigma-Aldrich). ATP was quantified 
as arbitrary light units and converted into nmol ATP/mg 
cell or mitochondrial proteins, according to the calibration 
curve previously set.
Respiratory chain activity
Mitochondria were extracted as described 
earlier [52]. A 50 μl aliquot was sonicated and used for the 
measurement of protein content or Western blotting; the 
remaining part was stored at −80°C until use. To confirm 
the presence of mitochondrial proteins in the extracts, 
10 μg of each sonicated sample was subjected to SDS-
PAGE and probed with an anti-porin antibody (Abcam; 
data not shown). The electron flux from Complex I to 
Complex III was measured on 10 μg of not sonicated 
mitochondrial extracts, as reported in [52]. Each sample 
was incubated in the absence or presence of the Complex 
I inhibitor rotenone (50 μM), to measure the ubiquinone-
independent and the ubiquinone-dependent electron flux, 
respectively. The reaction was followed for 5 min, using 
a Packard EL340 microplate reader (Bio-Tek Instruments, 
Winooski, VT). Results were expressed as nmol reduced 
cytochrome c/min/mg mitochondrial proteins.
Oxidative stress measurement
The evaluation of ROS was detected by using DHE, 
a specific marker for the determination of superoxide 
anion [53]. Once oxidized within the cell, DHE is 
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converted into ethidium and emits at the wavelength 
of 605 nm. 2 × 105 cells were incubated for 1 h with 
20 ng/ml DHE, trypsinized, washed twice with PBS and 
re-suspended in 500 μl of PBS. The dye accumulation was 
analyzed by a BD FACSCalibur flow cytometer (Becton 
Dickinson), using the FL2-channel (band pass filter: 
585 nm). For each sample, 2 × 104 events were acquired. 
H2O2, chosen as a compound that increases ROS in both 
chemosensitive and MDR cells; doxorubicin, chosen as a 
compound that increases ROS in chemosensitive but not 
in MDR cells; NAC, chosen as an antioxidant agent, were 
included as internal controls in each experiment.
Doxorubicin efflux rate
The kinetic parameters of doxorubicin efflux were 
calculated as previously reported [43]. Values were fitted 
to Michaelis-Menten equation to calculate Vmax and 
Km, using the Enzfitter software (Biosoft Corporation, 
Cambridge, United Kingdom).
Intracellular drug content
Cells were incubated for 3 h with 5 μM doxorubicin, 
1 μCi/ml [14C]-carboplatin (20 Ci/mmol; Amersham 
Bioscience, Piscataway, NJ), 0.5 μCi/ml [3H]-gemcitabine 
(10 Ci/mmol; Moravek Biochemicals and Radiochemicals, 
Brea, CA), 10 μM mitoxantrone. Samples were washed 
twice in PBS, detached with trypsin, centrifuged at 
1,300 x g for 2 min and sonicated. The amount of [14C]-
carboplatin and [3H]-gemcitabine was measured using a 
Tri-Carb Liquid Scintillation Analyzer (PerkinElmer). 
Radioactivity was converted in nmol/mg cell proteins 
for [14C]-carboplatin or pmol/mg cell proteins for [3H]-
gemcitabine, using a calibration curve previously prepared. 
The amount of doxorubicin and mitoxantrone was 
measured fluorimetrically, using a LS-5 spectrofluorimeter 
(PerkinElmer). Excitation and emission wavelengths were: 
475 nm and 553 nm (doxorubicin); 607 nm and 684 nm 
(mitoxantrone). Fluorescence was converted in nmol/mg 
cell proteins, using a calibration curve previously set.
FPPS silencing
5 × 104 A549/MDR cells were transduced with 
2.5 μg Tet-On pTRIPZ vector containing a specific shRNA 
for FPPS or a non targeting sequence (Thermo Scientific 
Open Biosystems, Waltham, MA). Transduced clones were 
selected by culturing cells in medium containing 0.5 μg/ml 
puromycin. FPPS shRNA was induced by adding 1 μg/ml 
doxycycline for 48 h. The silencing efficacy was checked 
by Western blot analysis.
In Vivo Tumor Growth
1 × 106 A549 and A549/MDR cells, re-suspended 
in 20 μl culture medium mixed with 20 μl Cultrex 
BME (Trevigen, Gaithersburg, MD), were implanted 
subcutaneously in 6 weeks-old female nude BALB/c 
mice, housed under 12 h light/dark cycle, with food and 
drinking provided ad libitum. When the tumors reached 
the volume of 100 mm3, the animals were randomized 
into these groups: control group (treated with 20 μl saline 
solution i.v. on days 2, 8, 14); NZ group (treated with 
20 μg/mouse NZ i.v. on days 2, 8, 14); doxorubicin group 
(treated with 4 mg/kg doxorubicin i.v. on days 3, 9, 15); 
NZ + doxorubicin group (treated with 20 μg/mouse NZ 
on days 2, 8, 14 followed by 4 mg/kg doxorubicin on days 
3, 9, 15); carboplatin group (treated with 50 mg/kg 
carboplatin i.v. on days 3, 9, 15); NZ + carboplatin group 
(treated with 20 μg/mouse NZ on days 2, 8, 14 followed 
by 50 mg/kg carboplatin on days 3, 9, 15). In a second 
experimental set, A549/MDR cells inducibly silenced 
for FPPS were implanted and mice were treated with 
doxorubicin or carboplatin as reported above. FPPS 
silencing was induced by adding doxycycline (1 mg/ml) 
in the drinking water. Tumor growth was measured by 
caliper and was calculated according to the equation: 
(L × W2)/2, where L = tumor length and W = tumor width. 
Mice were euthanized at day 21. The hematochemical 
parameters LDH, aspartate aminotransferase (AST), 
alanine aminotransferase (ALT), alkaline phosphatase 
(AP), creatine phosphokinase (CPK), creatinine were 
measured on 0.5 ml of blood collected immediately after 
mice sacrifice, using commercially available kits from 
Beckman Coulter Inc. (Brea, CA). The experimental 
procedures were approved by the Bioethics Committee 
(“Comitato Etico di Ateneo”) of the University of Torino, 
Italy.
Statistical analysis
All data in text and figures are provided as means 
± SD. The results were analyzed by a one-way analysis 
of variance (ANOVA) and Tukey’s test. p < 0.05 was 
considered significant.
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SUPPLEMENTARY FIGURES AND TABLES
Supplementary Figure S1: Expression of ABC transporters in chemosensitive and MDR cancer cells. Chemosensitive 
human lung cancer A549 cells and their resistant counterpart A549/MDR cells were lysed and subjected to the Western blot analysis for 
Pgp/ABCB1, MRP1/ABCC1, MRP2/ABCC2, MRP3/ABCC3, MRP4/ABCC4, MRP5/ABCC5, BCRP/ABCG2. The β-tubulin expression 
was used as control of equal protein loading. The figure is representative of 3 experiments.
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Supplementary Figure S2: Expression of ABC transporters after treatment with ZA and NZ in chemosensitive and 
MDR cancer cells. Chemosensitive human lung cancer A549 cells and their resistant counterpart A549/MDR cells were cultured for 
48 h in fresh medium (-), in medium containing 1 μM zoledronic acid (ZA) or 1 μM self-assembling ZA formulation (NZ), then lysed and 
subjected to the Western blot analysis for Pgp/ABCB1, MRP1/ABCC1, MRP2/ABCC2, MRP3/ABCC3, MRP4/ABCC4, MRP5/ABCC5, 
BCRP/ABCG2. The β-tubulin expression was used as control of equal protein loading. The figure is representative of 3 experiments.
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Supplementary Figure S3: Expression of HIF-1α-target genes in chemosensitive and MDR cancer cells treated with 
ZA and NZ. Chemosensitive human lung cancer A549 cells and their resistant counterpart A549/MDR cells were cultured for 48 h in 
fresh medium (-), in medium containing 1 μM zoledronic acid (ZA) or 1 μM self-assembling ZA formulation (NZ). VEGF, EPO, CA IX, CA 
XII mRNA levels were detected in triplicate by qRT-PCR. Data are presented as means ± SD (n = 4). For all panels, versus untreated A549 
cells: *p < 0.05; versus untreated A549/MDR cells: °p < 0.02.
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Supplementary Figure S4: Effects of empty self assembling liposomes on chemosensitive and MDR cancer 
cells. Chemosensitive human lung cancer A549 cells and their resistant counterpart A549/MDR cells were cultured for 48 h in fresh 
medium (-) or in medium containing self-assembling formulation without zoledronic acid (blank NPs, NB) at the same final concentration 
used in the all the other experimental assays. a. Cells were radiolabelled during the last 24 h with [3H]-acetate, then the de novo synthesis 
of cholesterol, FPP and ubiquinone was measured. Data are presented as means ± SD (n = 3). For all panels, A549/MDR cells versus A549 
cells: *p < 0.02. b. HIF-1α activity was measured in nuclear extracts by ELISA. Data are presented as means ± SD (n = 3). A549/MDR 
cells versus A549 cells: *p < 0.005. c. ATP levels in whole cell (total) and isolated mitochondria (mitochondrial) were measured by a 
chemiluminescence-based assay. Data are presented as means ± SD (n = 3). A549/MDR cells versus A549 cells: *p < 0.001. d. Pgp mRNA 
levels were detected in triplicate by qRT-PCR. Data are presented as means ± SD (n = 3). A549/MDR cells versus A549 cells: *p < 0.001. 
e. Cells were grown for 48 h in fresh medium or in medium containing blank NPs (NB), then incubated for 20 min with increasing 
concentrations (0–50 μmol/L) of doxorubicin (dox). Cells were washed and tested for the intracellular drugs content. The procedure was 
repeated on a second series of dishes, incubated in the same experimental conditions and analyzed after 10 min. Data are presented as means 
± SD (n = 3). The rate of doxorubicin efflux (dc/dt) was plotted versus the initial concentration of the drug.Vmax (nmol/min/mg proteins) 
and Km (nmol/mg proteins) were calculated with the Enzfitter software.
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Supplementary Figure S5: Effects of FPPS silencing on the synthesis of cholesterol, FPP and ubiquinone in 
chemoresistant cancer cells. Wild-type A549/MDR cells, cells treated with a TetON vector containing a shRNA targeting FPPS (sh) 
or with a non targeting shRNA vector (scr), were cultured 48 h in media without (- doxy) or with (+ doxy) 1 μg/ml doxycycline. Cells were 
radiolabelled during the last 24 h with [3H]-acetate, then the de novo synthesis of cholesterol (panel a), FPP (panel b) or ubiquinone (panel 
c) was measured. Data are presented as means ± SD (n = 3). For all panels, versus untreated (-, - doxy) cells: *p < 0.001.
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Supplementary Table S1: IC50 (μM) of different cytotoxic drugs in HT29 and HT29/MDR cells
Drug Transporter
HT29 HT29 HT29 HT29/MDR HT29/MDR HT29/MDR
CTRL ZA NZ CTRL ZA NZ
doxorubicin
Pgp, MRP1, 
MRP2, MRP3, 
BCRP
1.23 ± 0.08 0.91 ± 0.07 0.71 ± 0.1 * 2.58 ± 0.13° 1.02 ± 0.12 * 0.98 ± 0.07*
vinblastine Pgp, MRP1, MRP2 3.61 ± 0.14 2.53 ± 0.17 1.88 ± 0.14 * 9.23 ± 0.41° 3.21 ± 0.16 * 0.51 ± 0.09*
etoposide Pgp, MRP1, MRP2, MRP3 1.12 ± 0.15 0.67 ± 0.11 * 0.51 ± 0.06 *
11.41 ± 
0.37°
2.76 ± 0.44 * 2.33 ± 0.18*
irinotecan Pgp, MRP1, MRP2 6.23 ± 0.37 4.41 ± 0.31 3.71 ± 0.44 *
47.11 ± 
5.14° 36.11 ± 3.71
14.23 ± 
0.91*
cisplatin MRP1, MRP2, MRP4 10.89 ± 1.21 7.21 ± 0.88 6.01 ± 0.13 *
52.14 ± 
2.47°
5.88 ± 0.42 * 2.24 ± 0.55*
oxaliplatin MRP1, MRP4 5.87 ± 0.61 2.43 ± 0.52 * 0.91 ± 0.15 * 12.21 ± 0.18° 5.21 ± 0.23 * 0.81 ± 0.16*
5-fluorouracile
MRP1, MRP3, 
MRP4, MRP5 0.83 ± 0.11 0.61 ± 0.14 0.65 ± 0.13 7.53 ± 0.71° 5.44 ± 0.23 3.12 ± 0.14*
methotrexate
MRP4, Pgp, 
MRP1, MRP2, 
MRP3, BCRP
2.34 ± 0.31 1.01 ± 0.18 * 0.21 ± 0.09 * 8.79 ± 0.71° 1.77 ± 0.45 * 0.46 ± 0.22*
pemetrexed MRP5 0.74 ± 0.01 0.65 ± 0.17 0.12 ± 0.07 * 8.26 ± 0.57° 5.78 ± 0.56 1.33 ± 0.27*
gemcitabine MRP5 0.11 ± 0.03 0.11 ± 0.09 0.06 ± 0.01 * 0.75 ± 0.08° 0.21 ± 0.09 * 0.05 ± 0.02*
mitoxantrone BCRP, Pgp, MRP1 5.88 ± 0.41 2.21 ± 0.17 * 2.03 ± 0.21 * 9.67 ± 0.41° 4.53 ± 0.37 * 2.81 ± 0.41*
Untreated (CTRL) HT29 and HT29/MDR cells, cells treated with ZA or NZ (1 μM), were incubated for 72 h with increasing 
concentrations of cytotoxic drugs, then stained in quadruplicate with neutral red (n = 3). Versus respective CTRL: *p < 0.05; 
HT29/MDR versus HT29 cells: °p < 0.001.
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Supplementary Table S2: Hematochemical parameters of animals
LDH AST ALT AP CPK creatinine
(U/l) (U/l) (U/l) (U/l) (U/l) (mg/l)
A549 Ctrl 6342 ± 1567 267 ± 56 39 ± 12 75 ± 16 434 ± 68 0.05 ± 0.01
NZ 6872 ± 1812 293 ± 24 46 ± 11 87 ± 24 511 ± 76 0.06 ± 0.02
dox 7862 ± 2089 254 ± 34 41 ± 13 81 ± 23 897 ± 71* 0.05 ± 0.02
NZ+dox 6723 ± 1629 309 ± 31 50 ± 22 73 ± 27 911 ± 56* 0.06 ± 0.03
Pt 6341 ± 1098 311 ± 24 45 ± 17 76 ± 23 467 ± 71 0.09 ± 0.01*
NZ+Pt 6009 ± 1987 298 ± 66 49 ± 17 75 ± 11 509 ± 87 0.10 ± 0.02*
A549/MDR Ctrl 7098 ± 1803 288 ± 24 47± 18 78 ± 26 454 ± 91 0.04 ± 0.02
NZ 7612 ± 2137 291 ± 34 51 ± 16 87 ± 21 459 ± 37 0.06 ± 0.02
dox 6534 ± 1271 254 ± 71 45 ± 16 80± 14 434 ± 68 0.04 ± 0.01
NZ+dox 6093 ± 1234 312 ± 45 55 ± 23 80 ± 20 987 ± 99 * 0.05 ± 0.04
Pt 6092 ± 1261 324 ± 71 56 ± 25 77 ± 23 467 ± 93 0.08 ± 0.01*
NZ+Pt 6873 ± 1093 321 ± 81 47 ± 16 71 ± 34 489 ± 88 0.09 ± 0.02*
Six weeks old female BALB/c mice bearing a 100 mm3-tumor of A549 or A549/MDR cells were randomly divided in the 
following groups (5 mice/group) and treated with saline solution (Ctrl), NZ, doxorubicin (dox), NZ + doxorubicin (NZ+dox), 
carboplatin (Pt), NZ + carboplatin (NZ + Pt), as detailed under Materials and Methods. The experiment was repeated 2 times. 
The animals were sacrificed at day 21 after randomization. Blood was collected immediately after mice euthanasia. Versus 
Ctrl group: *p < 0.02.
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Supplementary Table S3: Primers sequence for qRT-PCR
Gene Forward primer Reverse primer
GLUT1 CCTGCAGTTTGGCTACAACA TAACGAAAAGGCCCACAGAG
HK AGACGCACCCACAGTATTCC CGCATCCTCTTCTTCACCTC
PFK1 GGAGCTTCGAGAACAACTGG CTGTGTGTCCATGGGAGATG
ALDO-A GCTATGGCCTTTTCCTTTCC ATGCTCCCAGTGGACTCATC
GAPDH GAAGGTGAAGGTCGGAGT CATGGTGGAATCATATTGGAA
PGK TCTCATGGATGAGGTGGTGA CTTCCAGGAGCTCCAAACTG
ENO-A GCTCCGGGACAATGATAAGA TCCATCCATCTCGATCATCA
PK TGCAGTGGAGCTCAGAGAGA GCTTCCGGTGACATAATGCT
LDH TGGGAGTTCACCCATTAAGC AGCACTCTCAACCACCTGCT
VEGF ATCTTCAAGCCATCCTGTGTGC GCTCACCGCCTCGGCTTGT
EPO CAGACTTCTACGGCCTGCTG GCTGAACACTGCAGCTTGAA
CA IX GTCTCGCTTGGAAGAAATCG AGAGGGTGTGGAGCTGCTTA
CA XII ACTGAGTCTCTGGGCATCATCC AAAAGCCAAATGGACACCAC
Pgp TGCTGGAGCGGTTCTACG ATAGGCAATGTTCTCAGCAATG
S14 GGTGCAAGGAGCTGGGTAT TCCAGGGGTCTTGGTCCTATTT
